CORMEDIX INC (CRMD)
US21900C3088 - Common Stock
ChartMill assigns a Buy % Consensus number of 82% to CRMD. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 13.26. This target is 148.78% above the current price.
CRMD was analyzed by 10 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about CRMD.
In the previous month the buy percentage consensus was at a similar level.
CRMD was analyzed by 10 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-04-09 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-04-09 | Needham | Reiterate | Buy -> Buy |
| 2024-03-13 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-03-12 | Needham | Maintains | Buy -> Buy |
| 2024-01-31 | Truist Securities | Maintains | Buy -> Buy |
| 2023-11-15 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2023-11-15 | Needham | Maintains | Buy -> Buy |
| 2023-11-15 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-11-15 | Truist Securities | Reiterate | Buy -> Buy |
| 2023-08-10 | RBC Capital | Initiate | Outperform |
| 2023-08-08 | Needham | Maintains | Buy -> Buy |
| 2023-06-21 | Needham | Reiterate | Buy -> Buy |
| 2023-05-19 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2023-05-16 | Needham | Reiterate | Buy -> Buy |
| 2023-03-31 | JMP Securities | Reiterate | Market Outperform |
| 2023-03-31 | Needham | Reiterate | Buy |
| 2023-03-03 | Needham | Reiterate | Buy |
| 2023-03-01 | JMP Securities | Maintains | Market Perform |
| 2022-11-11 | Needham | Maintains | Buy |
| 2022-08-12 | Truist Securities | Maintains | Buy |
| 2022-08-09 | JMP Securities | Maintains | Market Outperform |
| 2022-08-09 | Needham | Maintains | Buy |
| 2021-05-14 | Needham | Maintains | Buy |
| 2021-02-17 | Needham | Initiate | Buy |